HIMS vs NBIX · P/E 74, rev $1.36B vs P/E 45, rev $1.77B
Hims Hers Health Inc (HIMS) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Hims Hers Health Inc (HIMS) is a household & personal products company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported HIMS revenue for 2026-06-30 was $1.36B. Net income was -$178.4M. HIMS currently screens at market cap $11.04B and trailing P/E 73.9.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
HIMS currently screens at market cap $11.04B and trailing P/E 73.9. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the HIMS and NBIX stock pages for the full models.
Not investment advice.